OBR Daily Commentary - Multiple Myeloma

forumImage

Cancer Patient Sues Celgene For Thwarting Generic Versions Of Its Pricey Meds

(STAT Plus) June 15, 2017 - In what may be a first, a patient has filed a lawsuit accusing a drug maker of hiding behind a mandated safety program to thwart generic competition. The company, in this case, is Celgene.

Winston Wong, PharmD (Posted: June 16, 2017)

quotesThis sounds like the same play innovator manufacturers are playing in the biosimilar world, where the reference product is not being made available to biosimilar companies to conduct their comparative studies. One other point to be made here is was the increase in copay from $42 to $250 due to the price increase solely, or due to a change in the benefit design?quotes

Read Article arrow
Add Comment 1 Comment
forumImage

7 Key Cancer Trends For 2018

(Forbes) Dec 31, 2017 - Few doctors, even oncologists who subspecialize, can keep up with developments in the field.

Winston Wong, PharmD (Posted: January 02, 2018)

quotesThese 7 Key Trends are definitely a continuation of what we have seen through 2017. From a payer perspective, while the decrease in Chemotherapy is balanced by the increase in targeted therapy is technically true, in the end, the patient is receiving some treatment, which is driving cost. We all will have to deal with how to deal with rising cost. Is value-based payments in the future? Probably yes, but not the near future as we all need to determine a methodology to define value and outcomes. Payers will be put into more of a struggle as the number of tumor agnostic tests increases and payers need to modify their payment policies. And finally, patient outcomes and satisfaction will become part of the "value" equation.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Oncologists Getting 6% of Drug Price Is 'Financial Conflict'

(Medscape Medical News) Mar 7, 2018 - "No one is immune from $ temptation.... We have a system that rewards oncologists and their chemotherapy offices with more $ for giving more expensive chemo. This has to change," said Vincent Rajkumar, MD, a professor of medicine and a hematologist/oncologist at the Mayo Clinic, Rochester, Minnesota.

Dean Gesme, MD (Posted: March 07, 2018)

quotesI respect Dr Rajkumar's clinical expertise but here in MN we have a 2% state drug tax as well as the federal government's 2% sequester; hence ASP plus 6% is totally illusory. The 1.8% net margin is insufficent to cover drug ordering, wastage, bad debt and pharmacy overhead unless they were being subsidized by 340b rebates! Thus 340b rebates may be the real perverse inducement and not "ASP plus 6%".quotes

Read Article arrow
Add Comment 3 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...